The ALS Therapy Development Institute (ALS TDI) is proud to announce that the first participant was successfully given a dose of AT-1501 in the first clinical trial of the experimental treatment for amyotrophic lateral sclerosis (ALS). The phase 1 safety trial is enrolling healthy volunteers and people living with ALS, following the acceptance of an Investigational New Drug (IND) application by the Food & Drug Administration (FDA). A total of 8 people living with ALS will receive AT-1501 in this study, with the aim of determining safety and tolerability of the experimental antibody. The trial, sponsored by Anelixis Therapeutics, LLC, will also determine the pharmacokinetics of AT-1501, i.e. how the drug acts within the body.
When the ALS Therapy Development Institute invited me to speak at their annual White Coat Affair gala last October, I took advantage of the opportunity to tour the Institute’s lab where they are performing fast-track ALS research. While there, our tour passed by the freezer where AT-1501, a potential effective treatment for both ALS and Alzheimer’s, is stored.